Enjoy complimentary customisation on priority with our Enterprise License!
It has been observed that renal anemia is the significant reduction in the circulation of red blood cells in the body and is one of the most common symptoms of chronic kidney disease. During this condition, kidneys cannot produce erythropoietin, a hormone that prompts bone marrow to produce red blood cells. Red blood cells contain hemoglobin, which carries oxygen to the organs and tissues in the body. The red blood cells in the people with anemia carry less oxygen, thereby affecting the tissues and organs associated with the heart and brain.
Renal anemia, also known as anemia owing to chronic kidney disease (CKD), is the loss of kidney functions. The pathophysiology of anemia in CKD is characterized by conditions such as weakness, fatigue, and headache, affecting the heart and brain adversely. Several public and private companies are focused on the development of drug molecules for the treatment of renal anemia. Monotherapy is emerging as the most efficient approach for the treatment of renal anemia.
According to this pipeline analysis report, all the drug molecules in the pipeline are being developed for renal anemia. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of renal anemia. In addition to providing information on the various stages of molecules developed by companies for different indications, the pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are:
The oral route of administration (ROA) involves the administration of the drug directly into the mouth cavity, which will have a more direct effect on the target cells.
According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for renal anemia are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
PART 13: APPENDIX
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.